DYN

Company Overview — What Does Dyne Therapeutics, Inc. Do?

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. Dyne Therapeutics, Inc. (DYN) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joshua T. Brumm and employs approximately 100 people. With a market capitalization of $3.0B, DYN is one of the notable companies in the Healthcare sector.

Dyne Therapeutics, Inc. (DYN) Stock Rating — Hold (April 2026)

As of April 2026, Dyne Therapeutics, Inc. receives a Hold rating with a composite score of 32.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DYN ranks #1,922 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Dyne Therapeutics, Inc. ranks #203 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DYN Stock Price and 52-Week Range

Dyne Therapeutics, Inc. (DYN) currently trades at $18.70. The stock lost $0.66 (3.4%) in the most recent trading session. The 52-week high for DYN is $25.00, which means the stock is currently trading -25.2% from its annual peak. The 52-week low is $6.36, putting the stock 194.1% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is DYN Overvalued or Undervalued? — Valuation Analysis

Dyne Therapeutics, Inc. (DYN) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.08x, versus the sector average of 2.75x.

At current multiples, Dyne Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Dyne Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Dyne Therapeutics, Inc. (DYN) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -44.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -36.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DYN Debt, Balance Sheet, and Financial Health

Dyne Therapeutics, Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 22.25x, indicating strong short-term liquidity. Total debt on the balance sheet is $149M. Cash and equivalents stand at $574M.

DYN has a beta of 1.69, meaning it is more volatile than the broader market — a $10,000 investment in DYN would be expected to move 69.1% more than the S&P 500 on any given day. The stability factor score for Dyne Therapeutics, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Dyne Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Dyne Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.47. Net income for the quarter was $-431M. Operating income came in at $-458M.

In FY 2025, Dyne Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.47. Net income for the quarter was $-446M. Operating income came in at $-468M.

In Q3 2025, Dyne Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.76. Net income for the quarter was $-108M. Operating income came in at $-114M.

In Q2 2025, Dyne Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.97. Net income for the quarter was $-111M. Operating income came in at $-116M.

Over the past 8 quarters, Dyne Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DYN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DYN Dividend Yield and Income Analysis

Dyne Therapeutics, Inc. (DYN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DYN Momentum and Technical Analysis Profile

Dyne Therapeutics, Inc. (DYN) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

DYN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Dyne Therapeutics, Inc. (DYN) ranks #203 out of 838 stocks based on the Blank Capital composite score. This places DYN in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DYN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DYN vs S&P 500 (SPY) comparison to assess how Dyne Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

DYN Next Earnings Date

No upcoming earnings date has been announced for Dyne Therapeutics, Inc. (DYN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DYN? — Investment Thesis Summary

Dyne Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 21/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 21/100) increases portfolio risk.

In summary, Dyne Therapeutics, Inc. (DYN) earns a Hold rating with a composite score of 32.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DYN stock.

Related Resources for DYN Investors

Explore more research and tools: DYN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DYN head-to-head with peers: DYN vs AZN, DYN vs SLGL, DYN vs VMD.